ClinicalTrials.gg
CompletedNCT04325035SEISMiCUpdated Feb 4, 2025

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

A Phase 2 interventional study of Istaroxime and Placebo in Cardiogenic Shock, sponsored by Windtree Therapeutics. Completed at 13 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Windtree Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.

Read the detailed description

This is a pilot, multinational, multicenter, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of males or females 18 to 85 years of age, hospitalized for acute decompensated heart failure (ADHF) with persistent hypotension (systolic blood pressure [SBP] 70-100 mmHg for two hours).

Part A will dose all subjects for 24 hours with either 1.0 µg/kg/min or placebo; Part B will dose all subjects for 60 hours with two different regimens of istaroxime or placebo. Enrollment of Part A and Part B will be sequential.

Up to 30 sites in Part A; up to 15 sites in Part B. Sites may be located in Europe, Asia, South America, and North America.

02

Conditions studied

  • Cardiogenic Shock

Keywords

  • Pre-cardiogenic shock
  • Heart failure
03

In context

Shock, Cardiogenic

296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's enrollment of 90 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

Windtree Therapeutics is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical presentation consistent with SCAI Stage B pre-cardiogenic shock caused by acute decompensation of chronic systolic heart failure (due to arterial hypertension, ischemic heart disease or dilated cardiomyopathy), without evidence for an acute coronary syndrome.
  2. Signed form (ICF);
  3. Males and females, 18 to 85 years of age (inclusive);
  4. An admission for acute decompensated heart failure (ADHF) episode within 36 hours prior to randomization, defined as:

    1. Dyspnea, at rest or with minimal exertion;
    2. Congestion on chest x-ray or lung US with B-type natriuretic peptide (BNP) ≥ 400 pg/mL or NT-proBNP ≥ 1400 pg/mL; Elective admissions for medications tune up or procedures do not qualify as an ADHF admission.
  5. History of (LVEF) ≤ 40%;
  6. Persistent hypotension defined as:

    1. SBP of 75 to 90 mmHg (Part A) or 70 to 100 mmHg (Part B) for ≥ 2 hours prior to Screening;
    2. SBP does not decrease by > 7 mmHg on two separate measurements during the last 2 hours prior to randomization;
  7. Heart rate 75 to 150 bpm. If the subject is on a beta-blocker, the range is 60 to 150 bpm;
  8. Echocardiogram during initial hospitalization confirming ejection fraction ≤ 40% and no evidence of other pathology to confound interpretation of cardiac physiology (e.g., pericardial effusion);
  9. Subject is monitored by a Pulmonary Artery Catheter (PAC) at the time of randomization (Part B only).

Exclusion criteria

Exclusion Criteria:

  1. Cardiogenic shock of SCAI Stage C or worse
  2. Cardiogenic shock due to any other condition besides acute decompensation of chronic heart failure.
  3. Any of the following in the past 30 days: acute coronary syndrome, coronary revascularization, myocardial infarction (MI), coronary artery bypass graft (CABG), or percutaneous coronary intervention;
  4. Current (within 6 hours of Screening) or anticipated need for treatment with positive inotropic agents or vasopressors, renal support including ultrafiltration, or mechanical circulatory, ventilatory or renal support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device);
  5. Venous Lactate > 2 mmol/L;
  6. History of heart transplant or United Network for Organ Sharing (UNOS) priority 1a heart transplant listing
  7. Ongoing treatment with digoxin (if digoxin was stopped before signing the ICF and the digoxin plasma level is \< 0.5 ng/ml, the patient may be enrolled);
  8. Severe renal impairment (estimated (eGFR) \< 30 ml/min, calculated by the Modification of Diet in Renal Disease (MDRD) formula);
  9. to the study medication or any of its (including known lactose hypersensitivity) or any related medication;
  10. Stroke or (TIA) within 3 months;
  11. Active coronary ischemia;
  12. Any significant valvular disease (including any moderate or severe valvular stenosis, moderate or severe aortic or pulmonary regurgitation, stenosis or regurgitation);severe tricuspid or mitral regurgitation);
  13. Primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease;
  14. Admission for AHF triggered primarily by a correctable etiology such as significant arrhythmia, (inclusive of atrial fibrillation as the main reason for admission), infection, severe anemia, acute coronary syndrome, pulmonary embolism, exacerbation of (COPD), planned admission for device implantation, or over-diuresis as a cause of hypotension;
  15. Pericardial constriction or active pericarditis;
  16. Life-threatening ventricular arrhythmia or implantable cardioverter defibrillator (ICD) shock within the past month or history of sudden death within 6 months;
  17. Cardiac resynchronization therapy (CRT), ICD, or pacemaker implantation (or planned implantation) within the past 3 months;
  18. Sustained ventricular tachycardia in the last 3 months with no defibrillator;
  19. Sustained hypotension (SBP \< 70 mmHg) for at least 30 minutes from the time of arrival to the hospital;
  20. Severe pulmonary disease or cor pulmonale or other causes of isolated right-sided HF or not related to left ventricular dysfunction;
  21. Acute respiratory distress syndrome;
  22. Suspected sepsis; fever > 38°C or active infection requiring IV antimicrobial treatment;
  23. Body weight \< 40 kg or ≥ 150 kg;
  24. Laboratory exclusions:

    1. \< 9 g/dl,
    2. count \< 100,000/µl,
    3. Serum potassium > 5.3 mmol/l or \< 3.5 mmol/l;
  25. A \< 3 months based on the judgment of the investigator;
  26. Uncontrolled thyroid disease;
  27. Pregnant or breast-feeding;
  28. Ongoing drug or alcohol abuse;
  29. Participation in another interventional study within the past 30 days.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Istaroxime - Part A

    Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min

    Drug: Istaroxime

  • Placebo comparator
    Placebo - Part A

    Placebo (lactose lyophilized powder) IV infusion for 24 hours

    Drug: Placebo

  • Experimental
    Istaroxime - Part B

    Istaroxime IV infusion at 1.0 µg/kg/min for 6 hours, 0.5 µg/kg/min for 42 hours, 0.25 µg/kg/min for 12 hours.

    Drug: Istaroxime

  • Experimental
    Istaroxime and Placebo - Part B

    Istaroxime IV infusion at 0.5 µg/kg/min for 48 hours, followed by placebo IV infusion for 12 hours.

    Drug: Istaroxime · Drug: Placebo

  • Placebo comparator
    Placebo - Part B

    Placebo (lactose lyophilized powder) IV infusion for 60 hours.

    Drug: Placebo

Interventions

  • Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion

    Also known as: PST2744

  • DrugPlacebo

    Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion

    Also known as: Lactose lyophilized powder

06

What researchers measure

Primary outcomes

  1. Change from baseline in systolic blood pressure (SBP) area under the curve (AUC) 0-6

    Change from baseline AUC for systolic blood pressure

    Time frame: 0 to 6 hours after initiation of infusion

Secondary outcomes

  1. Change from baseline in SBP AUC 0-48

    Change from baseline in AUC for systolic blood pressure in Part B

    Time frame: 0 to 60 hours after initiation of infusion

  2. Change from baseline in SBP AUC 0-60

    Change from baseline in AUC for systolic blood pressure in Part B

    Time frame: 0 to 48 hours after initiation of infusion

  3. Treatment failure score

    Treatment-failure score, based on death, circulatory, respiratory, or renal mechanical support or intravenous inotrope or vasopressor treatment, and changes in systolic blood pressure

    Time frame: 60 hours from initiation of infusion

  4. Change from baseline in SBP

    Change from baseline in systolic blood pressure

    Time frame: 6 hours after initiation of infusion

  5. Change from baseline in SBP

    Change from baseline in systolic blood pressure

    Time frame: 24 hours after initiation of infusion

  6. Change from baseline in SBP

    Change from baseline in systolic blood pressure in Part B

    Time frame: 48 hours after initiation of infusion

  7. Change from baseline in SBP

    Change from baseline in systolic blood pressure in Part B

    Time frame: 60 hours after initiation of infusion

  8. Number of treatment failures

    Number of subjects requiring treatment with intravenous vasopressors, inotropes, and/or mechanical cardiac or renal support or have died

    Time frame: Randomization to 24 hours for Part A

  9. Number of treatment failures

    Number of subjects requiring treatment with intravenous vasopressors, inotropes, and/or mechanical cardiac or renal support or have died

    Time frame: Randomization to 48 hours for Part B

  10. Number of treatment failures

    Number of subjects requiring treatment with intravenous vasopressors, inotropes, and/or mechanical cardiac or renal support or have died

    Time frame: Randomization to Day 5

  11. Change in quality of life

    Changes from baseline measured by the EQ-5D in Part A

    Time frame: Baseline to Day 5 (96 hours) from infusion start

  12. Change in quality of life

    Changes from baseline measured by the EQ-5D in Part A

    Time frame: Baseline to Day 30 from infusion start

  13. Change in eGFR

    Change from baseline and observed estimated glomerular filtration rate (eGFR)

    Time frame: 24 hours from infusion start

  14. Change in eGFR

    Change from baseline and observed estimated glomerular filtration rate (eGFR)

    Time frame: 48 hours from infusion start

  15. Change in brain natriuretic peptide (BNP), N-terminal pro hormone B-type natriuretic peptide (NT-pro-BNP), troponin (cTn; either T or I) and venous lactate

    Change from baseline and observed BNP, NT-pro-BNP, troponin (cTn; either T or I) and venous lactate

    Time frame: 24 hours from infusion start

  16. Change in brain natriuretic peptide (BNP), N-terminal pro hormone B-type natriuretic peptide (NT-pro-BNP), troponin (cTn; either T or I) and venous lactate

    Change from baseline and observed BNP, NT-pro-BNP, troponin (cTn; either T or I) and venous lactate

    Time frame: 48 hours from infusion start

  17. Time to worsening heart failure (HF)

    Time to worsening HF

    Time frame: Up to Day 5

  18. Time to HF re-admission or death

    Time to HF re-admission or death

    Time frame: Up to Day 30

  19. Length of initial hospitalization

    Length of initial hospitalization

    Time frame: Up to Day 30

  20. Days alive and out of the hospital

    Days alive and out of the hospital

    Time frame: Up to Day 30

  21. Mortality and reasons for death

    Mortality and reasons for death

    Time frame: Up to Day 30

  22. Change in coronary index (CI)

    Change from baseline in CI as assessed by echocardiogram - Part A

    Time frame: 24 hours

  23. Change in E to e' ratio

    Change from baseline in E to e' ratio as assessed by echocardiogram - Part A

    Time frame: 24 hours

  24. Change in stroke volume index (SVI)

    Change from baseline in SVI as assessed by echocardiogram - Part A

    Time frame: 24 hours

  25. Change in left atrium area (LAA)

    Change from baseline in LAA as assessed by echocardiogram - Part A

    Time frame: 24 hours

  26. Change in CI

    Change from baseline in CI as assessed by echocardiogram - Part B

    Time frame: 48 hours

  27. Change in E to e' ratio

    Change from baseline in E to e' ratio as assessed by echocardiogram - Part B

    Time frame: 48 hours

  28. Change in SVI

    Change from baseline in SVI as assessed by echocardiogram - Part B

    Time frame: 48 hours

  29. Change in LAA

    Change from baseline in LAA as assessed by echocardiogram - Part B

    Time frame: 48 hours

07

Study locations

13 sites
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Hospital Italiano de Bueno Aires
    Capital Federal, Buenos Aires C1199, Argentina
  • Santorio Guemes
    Capital Federal, Buenos Aires CP1180, Argentina
  • Hospital Privado de Rosario
    Rosario, Sante Fe S20000GAP, Argentina
  • Instituto Cardiovascular de Rosario
    Rosario, Sante Fe S2000DSR, Argentina
  • Santorio de la Trinidad Palermo
    Buenos Aires, C1425, Argentina
  • Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo
    Alessandria, Italy
  • UOC Cardiologia, ASST degli Spedali Civili di Brescia Pizzale Spedali Civili 1
    Brescia, 25123, Italy
  • IRCCS San Raffaele Scientific Institute
    Milan, 20132, Italy
  • Uniwersytecki Szpital Kliniczny, Centrum Chorub Serca
    Wrocław, Dolnoslaskie 50-556, Poland
  • Uniwersytecki Szpital Kliniczny w Białymstoku
    Białystok, 15-276, Poland
  • Uniwersytecki Szpital Kliniczny w Opolu
    Opole, 45-401, Poland
  • 4 Wojskowy Szpital Kliniczny
    Wroclaw, 50-981, Poland
08

References and documents

Publications

  • Metra M, Chioncel O, Cotter G, Davison B, Filippatos G, Mebazaa A, Novosadova M, Ponikowski P, Simmons P, Soffer J, Simonson S. Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). Eur J Heart Fail. 2022 Oct;24(10):1967-1977. doi: 10.1002/ejhf.2629. Epub 2022 Aug 22. PubMed 35867804 ↗
  • Metra M, Chioncel O, Davison B, Filippatos G, Mebazaa A, Pagnesi M, Adamo M, Novosadova M, Ponikowski P, Simmons P, Soffer J, Simonson S, Cotter G. Safety and Efficacy of Istaroxime 1.0 and 1.5 microg/kg/min for Patients With Pre-Cardiogenic Shock. J Card Fail. 2023 Jul;29(7):1097-1103. doi: 10.1016/j.cardfail.2023.03.020. Epub 2023 Apr 17. PubMed 37075941 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Sep 2024, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2020
First posted
Mar 27, 2020
StartActual
Sep 28, 2020
Primary completionActual
Sep 26, 2024
CompletionActual
Oct 30, 2024
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04325035
Lead sponsor
Windtree Therapeutics
Collaborators
Momentum Research, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2020
Start date
Sep 28, 2020
Primary completion
Sep 26, 2024
Completion
Oct 30, 2024
Last update
Feb 4, 2025

Study contacts

Marco Metra, MD
principal investigator · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Istaroxime

Start the discussion